Company Overview and News

 
India looks to counter US curbs on Iran oil import

2018-09-21 freepressjournal.in
Washington : India is likely to resist the American pressure on complying with the reimposed Iranian sanctions as it has been a traditional policy of New Delhi to enforce only UNSC-authorised sanctions, a Congressional report has told lawmakers. The Trump administration has threatened entities and countries with consequences if they do not bring down their import of Iranian oil to zero by November 4.
IOC 500116 500325 IDBI RELIANCE RIGD 532505 530965 UCOBANK RLNIY

 
Refiners will pay for Iran oil in rupees after US sanctions kick in: Report

2018-09-20 moneycontrol
As petroleum-related sanctions on Iran come into effect from November 4, Indian refiners will pay for oil in Indian currency using UCO Bank and IDBI Bank, according to a report by The Economic Times.
IOC 500116 IDBI 532505 530965 UCOBANK

 
10 state banks get new MDs, CEOs

2018-09-20 freepressjournal.in
New Delhi : Mrutyunjay Mahapatra and Padmaja Chundru, both deputy managing directors in State Bank of India (SBI), have been appointed as managing director and chief executive officer of Syndicate Bank and Indian Bank respectively, according to an official order issued on Wednesday.
INDIANB UBNC UDBKL ALBK 532418 UBLS 532814 532505 SYNDIBANK 532276 532121 UBLA 532480 UCOBANK DENABANK ANDHRABANK SBAZ

 
RCom awaiting final govt approval for spectrum sharing and trading: Anil Ambani

2018-09-19 livemint
Mumbai: Reliance Communications Ltd (RCom) is awaiting final approvals for spectrum sharing and trading from the department of telecommunications (DoT) to sell its assets, chairman Anil Ambani told shareholders at the company’s annual general meeting on Tuesday. Speaking to shareholders, Ambani said that RCom’s other monetization measures, including the sale of telecom infrastructure and fibre to Reliance Jio Infocomm Ltd, were at an advanced stage.
YESBANK DB HTMEDIA 532505 532648 YYBKY 532712 CRARF 532662 PNJZY RCOM 532461 ACA PNB CRARY UCOBANK SBAZ

 
Dena Bank, Bajaj Corp, UCO Bank, MMTC, Jubilant Food top gainers among BSE Group A stocks

2018-09-18 moneycontrol
The Indian benchmark indices continues to trade in the red and have extended the earlier loses this Tuesday afternoon with the Nifty50 down 73 points and is trading at 11,304 while the Sensex is trading lower by 214 points at 37,370.
500429 GALLANTT 532726 532505 HINDUNILVR 533155 JUBLFOOD 532179 532121 CRPKY UNIPHOS JBLWY 500696 CORPBANK UCOBANK DENABANK

 
Sunil Hitech to go into bankruptcy motion - for excess use of Amex credit cards

2018-09-04 moneycontrol
The slowdown in the business cycle, which has resulted in several companies being put on the block, thanks to the government’s bankruptcy law, may claim one more victim.
SUNILHITEC UBNC ICICIBANK PNJZY 532461 532174 IBN 532505 PNB UCOBANK 532711

 
RBI#39;s Prompt Corrective Action framework could be reviewed, says ICICI chairman

2018-08-23 moneycontrol
Banks are hoping for a "review" of Reserve Bank of India's (RBI) prompt corrective action (PCA) framework - a measure to check banks' financial health, ICICI bank's chairman said on Thursday.
IOB 500116 UDBKL IBN IDBI ALBK UBLS 532505 532179 532388 ICICIBANK 532121 CRPKY 532174 UBLA 532480 CORPBANK UCOBANK DENABANK

 
Managing Directors for state banks named

2018-08-23 freepressjournal.in
Mumbai : Syndicate Bank’s executive director S S Mallikarjuna Rao is most likely to be appointed as the managing director and CEO of Allahabad Bank, according to sources.
INDIANB UDBKL ALBK 532418 UBLS 532814 532505 532179 SYNDIBANK 532276 532121 CRPKY UBLA 532480 CORPBANK UCOBANK DENABANK ANDHRABANK SBAZ

 
UCO Bank posts Q1 loss of ₹634 crore

2018-08-11 livemint
New Delhi: State-owned UCO Bank on Friday reported a net loss of ₹633.88 crore for the first quarter ended June 2018. This first quarter loss, however, has narrowed both on annual and sequential basis.
532505 UCOBANK

 
UCO Bank - Financial Result Updates

2018-08-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532505 UCOBANK

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...